Quote | BioAtla Inc. (NASDAQ:BCAB)
Last: | $1.89 |
---|---|
Change Percent: | -7.8% |
Open: | $2 |
Close: | $2.05 |
High: | $2 |
Low: | $1.57 |
Volume: | 1,185,309 |
Last Trade Date Time: | 07/17/2024 03:00:00 am |
News | BioAtla Inc. (NASDAQ:BCAB)
SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced it will host a virtual R&D Day ar...
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management w...
Message Board Posts | BioAtla Inc. (NASDAQ:BCAB)
Subject | By | Source | When |
---|---|---|---|
BCAB $2.47 Pfizer filed form 4 back in | DDHOUND | investorshub | 03/30/2023 5:31:49 PM |
BioAtla Announces $65 Million Underwritten Offering of its | crudeoil24 | investorshub | 11/04/2022 1:12:23 PM |
BioAtla Initiated at Market Outperform by JMP Securities | crudeoil24 | investorshub | 11/04/2022 1:02:44 PM |
BioAtla Reports Q3 2022 Cash Balance Of $178.1M | crudeoil24 | investorshub | 11/04/2022 1:01:55 PM |
In a report released today, Arthur He CFA | crudeoil24 | investorshub | 11/04/2022 1:00:53 PM |
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced it will host a virtual R&D Day ar...
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management w...
Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug High doses of evalstotug as either a monotherapy or in combination with PD1 are associated with manageable safety w...